The Significance of the Ipilimumab/Nivolumab Findings in Melanoma

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

The KEYNOTE-689 study showed pembrolizumab with standard of care significantly improved outcomes for resectable HNSCC, reducing recurrence or death by 27%.

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response alongside pembrolizumab.

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting its potential as a targeted treatment option.